Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis

Background & Aims: Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic response to...

Descripción completa

Detalles Bibliográficos
Autores: Garcia Garcia de Paredes, Ana|||0000-0001-5498-6280, Villanueva, Càndid|||0000-0002-3674-914X, Blanco, Carolina, Genescà Ferrer, Joan|||0000-0002-0831-8422, Manicardi, Nicolo, García-Pagán, JC.|||0000-0001-9032-4954, Calleja, Jose Luis|||0000-0002-2265-6591, Aracil, Carlos|||0000-0002-8228-9041, Morillas Cunill, Rosa Ma|||0000-0001-9117-5049, Poca Sans, Maria|||0000-0002-0235-1395, Peñas, Beatriz, Augustin Recio, Salvador|||0000-0002-3515-9033, Abraldes, Juan G.|||0000-0003-3421-937X, Alvarado-Tapias, Edilmar|||0000-0003-2036-6133, Royo, Félix, García-Bermejo, Mª Laura, Falcón-Pérez, Juan M.|||0000-0003-3133-0670, Bañares, Rafael|||0000-0002-0412-8437, Bosch, Jaime|||0000-0003-3414-0055, Gracia-Sancho, Jordi|||0000-0001-7736-4089, Albillos, Agustín|||0000-0001-9131-2592
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:270216
Acceso en línea:https://ddd.uab.cat/record/270216
https://dx.doi.org/urn:doi:10.1016/j.jhepr.2021.100368
Access Level:acceso abierto
Palabra clave:Ascites
Beta-blockers
Cirrhosis
MicroRNA
Portal hypertension
Descripción
Sumario:Background & Aims: Treatment with non-selective beta-blockers (NSBBs) reduces the risk of ascites, which is the most common decompensating event in cirrhosis. This study aimed to assess the ability of a serum microRNA (miRNA) signature to predict ascites formation and the hemodynamic response to NSBBs in compensated cirrhosis. Methods: Serum levels of miR-452-5p, miR-429, miR-885-5p, miR-181b-5p, and miR-122-5p were analyzed in patients with compensated cirrhosis (N = 105). Hepatic venous pressure gradient (HVPG) was measured at baseline, after intravenous propranolol, and 1 year after randomization to NSBBs (n = 52) or placebo (n = 53) (PREDESCI trial). miRNAs were analyzed at baseline and at 1 year. Results: Nineteen patients (18%) developed ascites, of whom 17 developed ascites after 1 year. miR-181b-5p levels at 1 year, but not at baseline, were higher in patients that developed ascites. The AUC of miR-181b-5p at 1 year to predict ascites was 0.7 (95% CI 0.59-0.78). miR-429 levels were lower at baseline in acute HVPG responders to NSBBs (AUC 0.65; 95% CI, 0.53-0.76), but levels at baseline and at 1 year were not associated with the HVPG response to NSBBs at 1 year. Conclusions: Serum miR-181b-5p is a promising non-invasive biomarker to identify patients with compensated cirrhosis at risk of ascites development. Lay summary: Ascites marks the transition from the compensated to decompensated stage in cirrhosis and indicates a worsening in prognosis. There are currently no easily accessible tools to identify patients with compensated cirrhosis at risk of developing ascites. We evaluated the levels of novel molecules termed microRNAs in the blood of patients with compensated cirrhosis and observed that miR-181b-5p can predict which patients are going to develop ascites.

Similares en LA Referencia